Should I buy or sell Pacific Biosciences of California stock right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last year. There are currently 5 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PACB shares. View PACB analyst ratings or view top-rated stocks .

What is Pacific Biosciences of California's stock price target for 2024?

13 brokers have issued 1-year price objectives for Pacific Biosciences of California's stock. Their PACB share price targets range from $2.50 to $15.00. On average, they predict the company's stock price to reach $9.05 in the next twelve months. This suggests a possible upside of 546.4% from the stock's current price. View analysts price targets for PACB or view top-rated stocks among Wall Street analysts .

How have PACB shares performed in 2024?

Pacific Biosciences of California's stock was trading at $9.81 at the start of the year. Since then, PACB shares have decreased by 85.7% and is now trading at $1.40. View the best growth stocks for 2024 here .

When is Pacific Biosciences of California's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our PACB earnings forecast .

How can I listen to Pacific Biosciences of California's earnings call?

Pacific Biosciences of California will be holding an earnings conference call on Thursday, May 9th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link .

How were Pacific Biosciences of California's earnings last quarter?

Pacific Biosciences of California, Inc. (NASDAQ:PACB) announced its earnings results on Thursday, February, 15th. The biotechnology company reported ($0.27) earnings per share for the quarter, topping analysts' consensus estimates of ($0.29) by $0.02. The biotechnology company earned $58.36 million during the quarter, compared to analysts' expectations of $57.96 million. Pacific Biosciences of California had a negative trailing twelve-month return on equity of 40.23% and a negative net margin of 152.97%. Pacific Biosciences of California's revenue for the quarter was up 113.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.35) EPS.

What ETFs hold Pacific Biosciences of California's stock?

ETFs with the largest weight of Pacific Biosciences of California (NASDAQ:PACB) stock in their portfolio include Global X Telemedicine & Digital Health ETF (EDOC) , Global X Genomics & Biotechnology ETF (GNOM) , ARK Genomic Revolution ETF (ARKG) , BNY Mellon Innovators ETF (BKIV) , AXS Green Alpha ETF (NXTE) , AltShares Event-Driven ET (EVNT) , ARK Innovation ETF (ARKK) and First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) .

What guidance has Pacific Biosciences of California issued on next quarter's earnings?

Pacific Biosciences of California updated its first quarter 2024 earnings guidance on Tuesday, April, 16th. The company provided EPS guidance of for the period. The company issued revenue guidance of $38.8 million-$38.8 million, compared to the consensus revenue estimate of $50.3 million.

What is Christian Henry's approval rating as Pacific Biosciences of California's CEO?

2 employees have rated Pacific Biosciences of California Chief Executive Officer Christian Henry on Glassdoor.com . Christian Henry has an approval rating of 100% among the company's employees. This puts Christian Henry in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Pacific Biosciences of California own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacific Biosciences of California investors own include Pfizer (PFE) , Gilead Sciences (GILD) , Illumina (ILMN) , Novavax (NVAX) , Advanced Micro Devices (AMD) , AT&T (T) , Inovio Pharmaceuticals (INO) , NVIDIA (NVDA) , Invitae (NVTA) and Tesla (TSLA) .

Who are Pacific Biosciences of California's major shareholders?

Pacific Biosciences of California's stock is owned by a number of institutional and retail investors. Top institutional investors include Bourne Lent Asset Management Inc. (0.24%), IMC Chicago LLC (0.00%) and Green Alpha Advisors LLC (0.02%). Insiders that own company stock include Christian O Henry, David W Meline, Kathy Ordonez , Michele Farmer, Oene Mark Van , Peter Fromen , Susan G Kim and William W Ericson . View institutional ownership trends .

How do I buy shares of Pacific Biosciences of California?

Shares of PACB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Does Pacific Biosciences of California have any subsidiaries?

The following companies are subsidiares of Pacific Biosciences of California: Circulomics, Omniome, PacBio Singapore PTE Limited, Pacific Biosciences (Shanghai) Co. Ltd., Pacific Biosciences Canada Limited, Pacific Biosciences Germany GmbH, Pacific Biosciences International LLC, Pacific Biosciences Japan GK, and Pacific Biosciences UK Limited. Read More

NASDAQ:PACB

Pacific Biosciences of California (PACB) Stock Price, News & Analysis

→ Uncover this 2024 Hidden Gem (From Tips4Traders) (Ad)

Free PACB Stock Alerts

$1.38

-0.02 (-1.42%)

(As of 09:04 AM ET)

Compare

Today's Range: $1.38
▼
$1.38
50-Day Range: $1.40
▼
$6.71
52-Week Range: $1.25
▼
$14.55

Volume: 159,813 shs
Average Volume: 9.50 million shs
Market Capitalization: $369.80 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.05

Get Pacific Biosciences of California alerts:

Pacific Biosciences of California MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.58 Rating Score
Upside/Downside: 546.4% Upside
$9.05 Price Target
Short Interest: Bearish
18.31% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.06
Based on 16 Articles This Week
Insider Trading: Selling Shares
$218,843 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.01) to ($0.85) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.92 out of 5 stars

Medical Sector

632nd out of 913 stocks

Analytical Instruments Industry

20th out of 26 stocks

3.3

Analyst's Opinion

Consensus Rating
Pacific Biosciences of California has received a consensus rating of Moderate Buy. The company's average rating score is 2.62, and is based on 8 buy ratings, 5 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Pacific Biosciences of California has only been the subject of 4 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
18.31% of the outstanding shares of Pacific Biosciences of California have been sold short.
Short Interest Ratio / Days to Cover
Pacific Biosciences of California has a short interest ratio ("days to cover") of 5.6.
Change versus previous month
Short interest in Pacific Biosciences of California has recently increased by 7.64%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Pacific Biosciences of California does not currently pay a dividend.
Dividend Growth
Pacific Biosciences of California does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PACB.

2.8

News and Social Media Coverage

News Sentiment
Pacific Biosciences of California has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 16 news articles for Pacific Biosciences of California this week, compared to 4 articles on an average week.
Search Interest
33 people have searched for PACB on MarketBeat in the last 30 days. This is an increase of 18% compared to the previous 30 days.
MarketBeat Follows
26 people have added Pacific Biosciences of California to their MarketBeat watchlist in the last 30 days. This is an increase of 160% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Pacific Biosciences of California insiders have sold 24.34% more of their company's stock than they have bought. Specifically, they have bought $176,000.00 in company stock and sold $218,843.00 in company stock.
Percentage Held by Insiders
Only 1.90% of the stock of Pacific Biosciences of California is held by insiders.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Pacific Biosciences of California are expected to grow in the coming year, from ($1.01) to ($0.85) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Pacific Biosciences of California is -1.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Pacific Biosciences of California is -1.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Pacific Biosciences of California has a P/B Ratio of 0.53. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Priority Gold

Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!

Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.

Click here for your free guide

About Pacific Biosciences of California Stock (NASDAQ:PACB)

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

PACB Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PACB Stock News Headlines

April 18, 2024 | americanbankingnews.com

Pacific Biosciences of California (NASDAQ:PACB) Upgraded to "Sell" at StockNews.com

April 18, 2024 | msn.com

Pacific Biosciences of California (PACB) Price Target Decreased by 18.15% to 9.01

April 18, 2024 | Darwin (Ad)

Your Next Portfolio Star: Revealing 2024's Top Stock Pick

We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)

April 17, 2024 | baystreet.ca

Mid-Week Wednesday's Most Active Buys

April 16, 2024 | finanznachrichten.de

Pacific Biosciences of California, Inc.: PacBio Announces Preliminary First Quarter 2024 Revenue and Updates 2024 Revenue Guidance

April 16, 2024 | investorplace.com

The Cathie Wood Stock Shuffle: 4 Names She's Loving, 3 She's Leaving

April 16, 2024 | msn.com

PacBio falls after issuing guidance below expectations

April 16, 2024 | markets.businessinsider.com

PacBio Q1 Prel. Revenue Nearly Flat, Annual Revenue Outlook Below View; Stock Down

April 18, 2024 | Darwin (Ad)

Your Next Portfolio Star: Revealing 2024's Top Stock Pick

April 16, 2024 | finance.yahoo.com

PacBio Announces Preliminary First Quarter 2024 Revenue and Updates 2024 Revenue Guidance

April 14, 2024 | americanbankingnews.com

Pacific Biosciences of California (NASDAQ:PACB) Sets New 52-Week Low at $3.15

April 11, 2024 | americanbankingnews.com

Pacific Biosciences of California (NASDAQ:PACB) PT Lowered to $7.00 at The Goldman Sachs Group

April 11, 2024 | americanbankingnews.com

Pacific Biosciences of California (NASDAQ:PACB) Price Target Cut to $3.00 by Analysts at Barclays

April 11, 2024 | americanbankingnews.com

Pacific Biosciences of California (NASDAQ:PACB) Shares Down 8.3% on Analyst Downgrade

April 9, 2024 | fool.ca

NASDAQ:PACB (Pacific Biosciences Of California)

April 3, 2024 | tmcnet.com

Saviynt Recognized on Inc. Magazine's List of the Pacific Region's Fastest-Growing Private Companies

March 27, 2024 | prnewswire.com

Estonia National Biobank Selects PacBio to Sequence 10,000 Whole Genomes

March 23, 2024 | finanznachrichten.de

Pacific Biosciences of California, Inc.: PacBio Grants Equity Incentive Award to New Employee

March 22, 2024 | prnewswire.com

PacBio Grants Equity Incentive Award to New Employee

March 21, 2024 | finance.yahoo.com

11 Oversold NASDAQ Stocks To Buy Right Now

March 15, 2024 | bizjournals.com

Special Report: Pacific Marine & Supply Co. commemorates 80 years with donation

March 14, 2024 | markets.businessinsider.com

Sangamo Biosciences Earns Buy Rating on Breakthrough Brain-Targeting Gene Therapy Capsid and Strategic Advancements

March 12, 2024 | benzinga.com

How Is The Market Feeling About Pacific Biosciences?

March 12, 2024 | finance.yahoo.com

PacBio Announces PureTarget™ Repeat Expansion Panel, Expanding its Portfolio of End-to-End Clinical Research Solutions

March 7, 2024 | finance.yahoo.com

Director David Meline Acquires 40,000 Shares of Pacific Biosciences of California Inc (PACB)

February 26, 2024 | prnewswire.com

PacBio to Present at Upcoming Investor Conferences

February 16, 2024 | finance.yahoo.com

Q4 2023 Pacific Biosciences of California Inc Earnings Call

See More Headlines

Receive PACB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pacific Biosciences of California and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/15/2024
Today: 4/17/2024
Next Earnings (Confirmed): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Analytical instruments
Sub-Industry: Life Sciences Tools & Services
Current Symbol: NASDAQ:PACB
CUSIP: 69404D10
CIK: 1299130
Web: www.pacb.com
Phone: (650) 521-8000
Fax: 302-636-5454
Employees: 796
Year Founded: 2004

Price Target and Rating

Average Stock Price Target: $9.05
High Stock Price Target: $15.00
Low Stock Price Target: $2.50
Potential Upside/Downside: +598.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.58
Research Coverage: 13 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.21)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-306,730,000.00
Net Margins: -152.97%
Pretax Margin: -158.67%
Return on Equity: -40.23%
Return on Assets: -15.24%

Debt

Debt-to-Equity Ratio: 1.27
Current Ratio: 7.81
Quick Ratio: 7.21

Sales & Book Value

Annual Sales: $200.52 million
Price / Sales: 1.87
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.62 per share
Price / Book: 0.53

Miscellaneous

Outstanding Shares: 267,952,000
Free Float: 264,201,000
Market Cap: $375.13 million
Optionable: Optionable
Beta: 1.83

Social Links

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Mr. Christian O. Henry M.B.A. (Age 56)
President, CEO & Director
Comp: $1.1M
Ms. Susan G. Kim (Age 47)
Chief Financial Officer
Comp: $564.87k
Mr. Mark Van Oene (Age 51)
Chief Operating Officer
Comp: $772.11k
Mr. Jeff Eidel (Age 47)
Chief Commercial Officer
Comp: $435.62k
Dr. Stephen Turner Ph.D. (Age 56)
Co-Founder
Comp: $341.25k
Ms. Michele Farmer CPA (Age 44)
VP & Chief Accounting Officer
Trevin Rard
Head of Investor Relations
Dr. Brett Atkins J.D.
Ph.D., General Counsel & Corporate Secretary
Ms. Natalie Welch
Chief People Officer
Dr. Denis Zaccarin Ph.D. (Age 58)
Senior Vice President of Research & Development
Comp: $510.77k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PACB Stock Analysis - Frequently Asked Questions

Should I buy or sell Pacific Biosciences of California stock right now?: 13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last year. There are currently 5 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PACB shares.
View PACB analyst ratings or view top-rated stocks.
What is Pacific Biosciences of California's stock price target for 2024?: 13 brokers have issued 1-year price objectives for Pacific Biosciences of California's stock. Their PACB share price targets range from $2.50 to $15.00. On average, they predict the company's stock price to reach $9.05 in the next twelve months. This suggests a possible upside of 546.4% from the stock's current price.
View analysts price targets for PACB or view top-rated stocks among Wall Street analysts.
How have PACB shares performed in 2024?: Pacific Biosciences of California's stock was trading at $9.81 at the start of the year. Since then, PACB shares have decreased by 85.7% and is now trading at $1.40.
View the best growth stocks for 2024 here.
When is Pacific Biosciences of California's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our PACB earnings forecast.
How can I listen to Pacific Biosciences of California's earnings call?: Pacific Biosciences of California will be holding an earnings conference call on Thursday, May 9th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link.
How were Pacific Biosciences of California's earnings last quarter?: Pacific Biosciences of California, Inc. (NASDAQ:PACB) announced its earnings results on Thursday, February, 15th. The biotechnology company reported ($0.27) earnings per share for the quarter, topping analysts' consensus estimates of ($0.29) by $0.02. The biotechnology company earned $58.36 million during the quarter, compared to analysts' expectations of $57.96 million. Pacific Biosciences of California had a negative trailing twelve-month return on equity of 40.23% and a negative net margin of 152.97%. Pacific Biosciences of California's revenue for the quarter was up 113.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.35) EPS.
What ETFs hold Pacific Biosciences of California's stock?: ETFs with the largest weight of Pacific Biosciences of California (NASDAQ:PACB) stock in their portfolio include Global X Telemedicine & Digital Health ETF (EDOC), Global X Genomics & Biotechnology ETF (GNOM), ARK Genomic Revolution ETF (ARKG), BNY Mellon Innovators ETF (BKIV), AXS Green Alpha ETF (NXTE), AltShares Event-Driven ET (EVNT), ARK Innovation ETF (ARKK) and First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).

What guidance has Pacific Biosciences of California issued on next quarter's earnings?: Pacific Biosciences of California updated its first quarter 2024 earnings guidance on Tuesday, April, 16th. The company provided EPS guidance of for the period. The company issued revenue guidance of $38.8 million-$38.8 million, compared to the consensus revenue estimate of $50.3 million.
What is Christian Henry's approval rating as Pacific Biosciences of California's CEO?: 2 employees have rated Pacific Biosciences of California Chief Executive Officer Christian Henry on Glassdoor.com. Christian Henry has an approval rating of 100% among the company's employees. This puts Christian Henry in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Pacific Biosciences of California own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Pacific Biosciences of California investors own include Pfizer (PFE), Gilead Sciences (GILD), Illumina (ILMN), Novavax (NVAX), Advanced Micro Devices (AMD), AT&T (T), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Invitae (NVTA) and Tesla (TSLA).
Who are Pacific Biosciences of California's major shareholders?: Pacific Biosciences of California's stock is owned by a number of institutional and retail investors. Top institutional investors include Bourne Lent Asset Management Inc. (0.24%), IMC Chicago LLC (0.00%) and Green Alpha Advisors LLC (0.02%). Insiders that own company stock include Christian O Henry, David W Meline, Kathy Ordonez, Michele Farmer, Oene Mark Van, Peter Fromen, Susan G Kim and William W Ericson.
View institutional ownership trends.
How do I buy shares of Pacific Biosciences of California?: Shares of PACB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
Does Pacific Biosciences of California have any subsidiaries?: The following companies are subsidiares of Pacific Biosciences of California: Circulomics, Omniome, PacBio Singapore PTE Limited, Pacific Biosciences (Shanghai) Co. Ltd., Pacific Biosciences Canada Limited, Pacific Biosciences Germany GmbH, Pacific Biosciences International LLC, Pacific Biosciences Japan GK, and Pacific Biosciences UK Limited.
Read More

This page (NASDAQ:PACB) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Pacific Biosciences of California (PACB) Stock Price, News & Analysis

Pacific Biosciences of California MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Pacific Biosciences of California Stock (NASDAQ:PACB)

PACB Stock Price History

PACB Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

PACB Stock Analysis - Frequently Asked Questions

Overall MarketRank^™